Pharmacology Research & Perspectives

Papers
(The H4-Index of Pharmacology Research & Perspectives is 22. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Diversity of molecular targets and signaling pathways for CBD122
Molnupiravir: A new candidate for COVID‐19 treatment73
“LONG COVID”—A hypothesis for understanding the biological basis and pharmacological treatment strategy67
Effect of remimazolam induction on hemodynamics in patients undergoing valve replacement surgery: A randomized, double‐blind, controlled trial59
Drug discovery: Insights from the invertebrate Caenorhabditis elegans48
Nucleotide analogues as inhibitors of SARS‐CoV Polymerase39
Introducing variability in targeting the microtubules: Review of current mechanisms and future directions in colchicine therapy37
Safety and nonclinical and clinical pharmacokinetics of PC945, a novel inhaled triazole antifungal agent36
The antimicrobial effect behind Cannabis sativa35
Strategies to apply 3Rs in preclinical testing30
Gut bacterial microbiome composition and statin intake—A systematic review30
Spermidine and spermine exert protective effects within the lung29
Kidney damage from nonsteroidal anti‐inflammatory drugs—Myth or truth? Review of selected literature28
Drug‐drug interactions with candidate medications used for COVID‐19 treatment: An overview27
Pharmacological hypothesis: TPC2 antagonist tetrandrine as a potential therapeutic agent for COVID‐1927
The affinity and selectivity of α‐adrenoceptor antagonists, antidepressants, and antipsychotics for the human α1A, α1B, and α1D‐adrenoceptors26
Biological drug therapy for ocular angiogenesis: Anti‐VEGF agents and novel strategies based on nanotechnology26
Adverse pregnancy outcomes associated with first‐trimester exposure to angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers: A systematic review and meta‐analysis26
The interacting physiology of COVID‐19 and the renin‐angiotensin‐aldosterone system: Key agents for treatment24
Probiotic lactobacilli in formulas and hygiene products for the health of the urogenital tract24
Inter‐ethnic differences in pharmacokinetics—is there more that unites than divides?23
Identification of the metabolites of ivermectin in humans22
Histamine in cancer immunology and immunotherapy. Current status and new perspectives22
CCN5 activation by free or encapsulated EGCG is required to render triple‐negative breast cancer cell viability and tumor progression22
0.038480043411255